On July 8, 2025, Humacyte, Inc. announced that Symvess has been awarded Electronic Catalog (ECAT) listing approval from the U.S. Defense Logistics Agency. This approval makes Symvess available to healthcare professionals treating military service members, veterans, and other patients receiving care at Department of Defense (DOD) and U.S. Department of Veterans Affairs facilities.
The ECAT system is an internet-based platform that provides federal agencies with access to manufacturers’ and distributors’ products. This listing significantly expands the market access for Symvess, which was approved by the FDA in December 2024 for extremity vascular trauma.
The approval means Symvess is now accessible to approximately 35 Military Treatment Facilities and 160 U.S. Department of Veterans Affairs hospitals. This development is expected to contribute to the commercial adoption of Symvess in a critical and high-need patient population.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.